Caribou Biosciences (NASDAQ:CRBU) Downgraded to "Sell" Rating by Wall Street Zen

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Caribou Biosciences Stock Performance

NASDAQ:CRBU traded up $0.04 during trading hours on Friday, hitting $1.16. The stock had a trading volume of 1,202,742 shares, compared to its average volume of 1,346,058. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.00. The company has a market cap of $107.88 million, a price-to-earnings ratio of -0.72 and a beta of 2.44. The business's 50 day moving average is $0.95 and its 200-day moving average is $1.25.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,490.84% and a negative return on equity of 55.70%. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. On average, sell-side analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Several large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in shares of Caribou Biosciences during the first quarter worth $61,000. Jacobs Levy Equity Management Inc. grew its position in Caribou Biosciences by 19.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock valued at $1,317,000 after purchasing an additional 234,052 shares in the last quarter. AQR Capital Management LLC grew its position in Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock valued at $480,000 after purchasing an additional 463,391 shares in the last quarter. Pale Fire Capital SE grew its position in Caribou Biosciences by 7.2% in the first quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after purchasing an additional 52,518 shares in the last quarter. Finally, Aberdeen Group plc grew its position in Caribou Biosciences by 126.5% in the first quarter. Aberdeen Group plc now owns 411,144 shares of the company's stock valued at $375,000 after purchasing an additional 229,657 shares in the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.